MicroRNA-141 Is a Biomarker for Progression of @entity957 and Adenocarcinoma of the Lung: Clinical Analysis of 125 XXXX .

@entity1 @entity5 @entity957 @entity1149 @entity2 @entity189 @entity3 @entity420
@entity2 is the most common @entity5 worldwide. MicroRNA has become an ideal biomarker for @entity5 diagnosis, prognosis and therapy. The relationship between microRNA-141 and @entity1149 ( @entity1149 ) is contradictory. Thus, in current study, we aimed to investigate the level of microRNA-141 in @entity1149 tissues and to evaluate its potential clinical value. This study enrolled 125 @entity1149 @entity1 (75 males and 50 females) with a median age of 61 years (range, 23-90 years). @entity1149 @entity1 included 23 @entity957 ( @entity957 ), 101 @entity420 ( @entity420 ) and 1 large cell @entity189 . The expression level of microRNA-141 was significantly higher in @entity1149 tissues than in adjacent lung tissues (P < 0.001), detected by real time RT-PCR. Receiver operating characteristic (ROC) exhibited a moderate diagnostic value of microRNA-141 for @entity1149 with the area under curve of 0.707. The microRNA-141 expression increased with the larger @entity5 size (P = 0.002), lymph node @entity3 (P = 0.018) and advanced stage (P = 0.022) in @entity1149 @entity1 . For subgroup analysis, microRNA-141 expression in SCC was correlated with @entity5 size (r = 0.490, P = 0.018), and in ADC, microRNA-141 level was positively associated with @entity5 size (r = 0.222, P = 0.026), lymph node @entity3 (r = 0.242, P = 0.015) and TNM stage (r = 0.210, P = 0.035). Furthermore, univariate analysis revealed that the expression of microRNA-141 was an independent prognostic indicator of ADC. In conclusion, microRNA-141 is a potential biomarker for the molecular diagnosis and risk stratification of @entity1149 .
